成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Anti-infection Metabolic Enzyme/Protease
  3. Bacterial Endogenous Metabolite
  4. 4-Hydroxycoumarin

4-Hydroxycoumarin  (Synonyms: 4-羥基香豆素)

目錄號(hào): HY-N6856 純度: 99.96%
COA 產(chǎn)品使用指南 技術(shù)支持

4-Hydroxycoumarin 是一種口服有活性的香豆素衍生物，最通用的雜環(huán)支架之一，常用于各種有機(jī)化合物的合成。4-Hydroxycoumarin 具有親電和親核性質(zhì)。4-Hydroxycoumarin 是 HIV 蛋白酶抑制劑和酪氨酸激酶抑制劑。4-Hydroxycoumarin 有抗炎、抗菌和抗腫瘤作用。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

4-Hydroxycoumarin Chemical Structure

4-Hydroxycoumarin Chemical Structure

CAS No. : 1076-38-6

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
Free Sample (0.1 - 0.2 mg)   Apply now  
10 mM * 1 mL in DMSO ￥550
In-stock
500 mg ￥500
In-stock
1 g   詢價(jià)  
5 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of 4-Hydroxycoumarin:

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

4-Hydroxycoumarin is an orally active coumarin derivative, one of the most versatile heterocyclic scaffolds, often used in the synthesis of various organic compounds. 4-Hydroxycoumarin possesses both electrophilic and nucleophilic properties. 4-Hydroxycoumarin is an HIV protease inhibitor and tyrosine kinase inhibitor. 4-Hydroxycoumarin has anti-inflammatory, antibacterial and anti-tumor effects[1][2][3][4].

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
EA.hy 926 EC50
> 200 μM
Compound: 3, 4-HC
Cytotoxicity against human EAhy926 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human EAhy926 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 24721833]
EA.hy 926 EC50
> 200 μM
Compound: 3, 4-HC
Cytotoxicity against human EAhy926 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human EAhy926 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 24721833]
LNCaP EC50
100.51 μM
Compound: 3, 4-HC
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 24721833]
LNCaP EC50
120.27 μM
Compound: 3, 4-HC
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 24721833]
MCF7 EC50
> 200 μM
Compound: 3, 4-HC
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 24721833]
MCF7 EC50
199.82 μM
Compound: 3, 4-HC
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 24721833]
MCF7 GI50
95.34 μM
Compound: 4a
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 28041801]
MDA-MB-231 EC50
> 200 μM
Compound: 3, 4-HC
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 24721833]
MDA-MB-231 EC50
100.26 μM
Compound: 3, 4-HC
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 24721833]
PC-3 EC50
150.46 μM
Compound: 3, 4-HC
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 24721833]
PC-3 EC50
173.31 μM
Compound: 3, 4-HC
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 24721833]
SK-MEL-28 IC50
1.3 μM
Compound: 9
Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 37197457]
SK-MEL3 IC50
2.1 μM
Compound: 9
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
[PMID: 37197457]
TK-10 GI50
> 100 μM
Compound: 4a
Cytotoxicity against human TK10 cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human TK10 cells assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 28041801]
U-937 EC50
> 200 μM
Compound: 3, 4-HC
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by Alamar blue assay
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 48 hrs by Alamar blue assay
[PMID: 24721833]
U-937 EC50
164.12 μM
Compound: 3, 4-HC
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay
Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay
[PMID: 24721833]
UACC-62 GI50
83.6 μM
Compound: 4a
Cytotoxicity against human UACC62 cells assessed as cell growth inhibition after 48 hrs by SRB assay
Cytotoxicity against human UACC62 cells assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 28041801]
體外研究
(In Vitro)

4-Hydroxycoumarin (0, 50, 160, 500 μM, 24 h) 在 B16-F10 黑色素瘤細(xì)胞中破壞肌動(dòng)蛋白細(xì)胞骨架，在 B82 成纖維細(xì)胞中沒(méi)有破壞，但可以降低它們對(duì)細(xì)胞外基質(zhì)蛋白的粘附和運(yùn)動(dòng)[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: B16-F10, B82
Concentration: 0, 50, 160, 500 μM
Incubation Time: 24 h
Result: Had no appreciable effect on cell viability.

Western Blot Analysis [2]

Cell Line: B16-F10
Concentration: 0, 50, 160, 500 μM
Incubation Time: 24 h
Result: Reduced the adhesion to ECM proteins and the tyrosine phosphorylation of several proteins in a concentration-dependent manner.
Inhibited the migration at 500 μM.
體內(nèi)研究
(In Vivo)

4-Hydroxycoumarin (10, 20 或 40 mg/kg/天, 灌胃) 在黑色素瘤小鼠中能有效地抑制腫瘤生長(zhǎng)，提高生存率[3]。
4-Hydroxycoumarin (5, 10, 25, 50 mg/kg/天, 口服) 在三硝基苯磺酸引起的大鼠結(jié)腸炎模型中能顯著減輕癥狀[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Mouse melanoma model[3]
Dosage: 10, 20 or 40 mg/kg
Administration: i.g.
Result: Reduced >85% of the number of pulmonary tumors.
Diminished the tumor size from day 22 and increased survival time at 10 mg/kg/day.
Animal Model: Rat colitis model [4]
Dosage: 5, 10, 25, 50 mg/kg
Administration: p.o.
Result: Reduced damage score and extension of the lesion at doses of 10 and 25 mg/kg.
Counteracted GSH content and reduced AP activity at a dose of 5 mg/kg.
Showed a good recovery of the intestinal cytoarchitecture at doses of 5 and 25 mg/kg.
分子量

162.14

Formula

C9H6O3
CAS 號(hào)
性狀

固體

顏色

White to off-white

中文名稱

4-羥基香豆素
結(jié)構(gòu)分類
初始來(lái)源
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.
儲(chǔ)存方式

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn)： 

DMSO 中的溶解度 : 100 mg/mL (616.75 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 6.1675 mL 30.8375 mL 61.6751 mL
5 mM 1.2335 mL 6.1675 mL 12.3350 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

  • 方案 一

    請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (12.83 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (12.83 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只
由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.96%

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 6.1675 mL 30.8375 mL 61.6751 mL 154.1877 mL
5 mM 1.2335 mL 6.1675 mL 12.3350 mL 30.8375 mL
10 mM 0.6168 mL 3.0838 mL 6.1675 mL 15.4188 mL
15 mM 0.4112 mL 2.0558 mL 4.1117 mL 10.2792 mL
20 mM 0.3084 mL 1.5419 mL 3.0838 mL 7.7094 mL
25 mM 0.2467 mL 1.2335 mL 2.4670 mL 6.1675 mL
30 mM 0.2056 mL 1.0279 mL 2.0558 mL 5.1396 mL
40 mM 0.1542 mL 0.7709 mL 1.5419 mL 3.8547 mL
50 mM 0.1234 mL 0.6168 mL 1.2335 mL 3.0838 mL
60 mM 0.1028 mL 0.5140 mL 1.0279 mL 2.5698 mL
80 mM 0.0771 mL 0.3855 mL 0.7709 mL 1.9273 mL
100 mM 0.0617 mL 0.3084 mL 0.6168 mL 1.5419 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
4-Hydroxycoumarin
目錄號(hào)：
HY-N6856
需求量：